The House of Haptics is being tested again. Immersion is ready to do battle with Motorola

Immersion Beat Sony and Microsoft in a Patent battle. Motorola is willing to see how they do.

Immersion Files Complaint Against Motorola Mobility With u.s. International Trade Commission Immersion Corporation (Nasdaq:IMMR), a leading developer and licensor of touch feedback technology, today announced that it has filed a complaint with the u.s. International Trade Commission (“itc”) against Motorola Mobility (Nasdaq: mmi). The complaint alleges that certain Motorola Mobility Android-based smartphones infringe six Immersion patents that cover various uses of haptic effects in connection with touchscreens. Immersion has also filed a patent infringement complaint against Motorola Mobility in the u.s. District Court for the District of Delaware. “Immersion has been a leading innovator in the field of haptic technology since its inception in 1993,” said Immersion’s ceo, Victor Viegas. “We have licensed our intellectual property portfolio and solutions with top tier manufacturers in the mobile space for 7 years and have seen nearly 400 million devices from our customers containing our technology come to market.” “Our primary interest is not to disrupt the availability of any product but to obtain compensation for the unauthorized use of our patents. Our preference has always been to negotiate a fair and reasonable agreement, and we remain open to negotiations,” continued Viegas. “However, despite having engaged in good faith efforts to license our patents to Motorola Mobility, we have not been able to reach an acceptable resolution, and therefore it is imperative that we protect our intellectual property and the interests of our shareholders.” In the complaint against Motorola Mobility, Immersion is seeking from the itc an exclusion order preventing the importation of infringing devices. In the suit against Motorola Mobility in the u.s. District Court, Immersion is alleging infringement of the same patents and is seeking to stop Motorola Mobility from further infringement, as well as the recovery of damages. The complaints against Motorola Mobility assert infringement of the following patents: U.S. Patent No 6,429,846: “Haptic Feedback for Touchpads and Other Touch Controls” U.S. Patent No 7,592,999: “Haptic Feedback for Touchpads and Other Touch Controls” U.S. Patent No 7,969,288: “Force Feedback System Including Multi-Tasking Graphical Host Environment and Interface Device” U.S. Patent No 7,982,720: “Haptic Feedback for Touchpads and Other Touch Controls” U.S. Patent No 8,031,181: “Haptic Feedback for Touchpads and Other Touch Controls” U.S. Patent No 8,059,105: “Haptic Feedback for Touchpads and Other Touch Controls”  About Immersion (www.immersion.com) Founded in 1993, Immersion (nasdaq: immr) is the leading innovator in haptic technology; the company's touch feedback solutions deliver a more compelling sense of the digital world. Using Immersion's high-fidelity haptic systems, partners can transform user experiences with unique and customizable touch feedback effects; excite the senses in games, videos and music; restore "mechanical" feel by providing intuitive and unmistakable confirmation; improve safety by overcoming distractions while driving or performing a medical procedure; and expand usability when audio and visual feedback are ineffective. Immersion's TouchSense technology provides haptics in mobile phone, automotive, gaming, medical and consumer electronics products from world-class companies. With over 1,200 issued or pending patents in the u.s. and other countries, Immersion helps bring the digital universe to life. Forward-looking Statements This press release contains "forward-looking statements" that involve risks and uncertainties as well as assumptions that, if they never materialize or prove incorrect, could cause the results of Immersion Corporation and its consolidated subsidiaries to differ materially from those expressed or implied by such forward-looking statements. All statements, other than the statements of historical fact, are statements that may be deemed forward-looking statements, including, but not limited to, the statement regarding remedies sought from the u.s. International Trade Commission and the u.s. District Court for the District of Delaware. Immersion's actual results might differ materially from those stated or implied by such forward-looking statements due to risks and uncertainties associated with Immersion's business, which include, but are not limited to, unexpected difficulties and costs related to continued disruption in the markets for Immersion's and its licensees' products due to the recent earthquake and tsunami in Japan; delay in or failure to achieve commercial demand for Immersion's or its licensees' products; a delay in or failure to achieve the acceptance of force feedback as a critical user experience; unexpected difficulties in transitioning to a pure ip licensing model and in monetizing the patent portfolio; the commercial success of applications or devices into which Immersion's technology is licensed; potentially lengthy sales cycles and design processes; unanticipated difficulties and challenges encountered in development efforts; potential restructuring charges; failure to retain key personnel; potential and actual claims and proceedings, including stockholder litigation; competition; the impact of global economic conditions and other factors. Many of these risks and uncertainties are beyond the control of Immersion. For a more detailed discussion of these factors, and other factors that could cause actual results to vary materially, interested parties should review the risk factors listed in Immersion's Annual Report on Form 10-k for 2010 and its most recent Quarterly Report on Form 10-q, which are on file with the u.s. Securities and Exchange Commission. The forward-looking statements in this press release reflect Immersion's beliefs and predictions as of the date of this release. Immersion disclaims any obligation to update these forward-looking statements as a result of financial, business, or any other developments occurring after the date of this release. Immersion, the Immersion logo, and TouchSense are trademarks of Immersion Corporation in the United States and other countries. All other trademarks are the property of their respective owners. (IMMR – t)

......................... Enjoy and Stay Profitable, Mark Kabbash CEO Equitygroups.com Your Investor Social Network Follow Me http://twitter.com/#!/EquityGroups4U I am not an investment adviser.  Please check with your broker also please check the disclaimers within this site.  http://bit.ly/igC0Cs Any suggestions or comments?  Please send them to me.

Electric Vechicle Model x Fasting Selling Tesla (TSLA) Ever

Model x, Fastest Selling Tesla Ever Electric Vehicles PALO alto, ca -- (Marketwire) -- 02/14/12 -- Tesla Motors (nasdaq: tsla) unveiled the highly anticipated Model x last Thursday evening at its Design Studio in Southern California. One day after the reveal, without any advertising, advance sales of the Model x exceeded $40 million. The compelling nature of the product created massive media attention and resulted in the Model x being the third most searched term on Google. On Thursday evening, the night of the reveal, traffic to teslamotors.com increased 2800 percent. Two-thirds of all visitors were new to the website. Electric Vehicles Proof that Model s and Model x are complementary products, new Model s reservations following the Model x unveiling were up 30 percent. Model x is equipped with unique Falcon Wing doors that open up and out of the way, allowing one to stand up in the second row and step directly to the third row. Built on the same platform as Model s, but with a longer wheelbase, Model x has approximately the same external dimensions of an Audi q7. On the inside, however, Model x has 40% more room than a q7 and is capable of carrying both seven large adults and considerable luggage. Electric Vehicles It will offer dual motor all wheel drive for superior all-weather driving and the option of a 60 or 85 kWh battery. The Model x Performance version will accelerate from 0 to 60 miles per hour in 4.4 seconds. This would make Model x faster than many sports cars, including the Porsche 911 Carrera. Matched with superior handling resulting from its low center of gravity, Model x will offer a remarkable combination of functionality, style and performance. Tesla's touchscreen, the 17" in-dash display that includes driver controls, vehicle apps, web connectivity and onboard charging are included in Model x Electric Vehicles. Model x will be priced competitively with other premium SUVs. It will be built at the Tesla Factory in Fremont, ca. Production begins at the end of 2013, deliveries begin early 2014, with volumes targeted at 10,000 - 15,000 units per year. About Tesla Tesla's goal is to accelerate the world's transition to electric mobility. Palo Alto, California based Tesla designs and manufactures EVs and ev power train components for partners such as Toyota and Daimler. Tesla has delivered more than 2,000 Roadsters to customers worldwide. Model s, the first premium sedan to be built from the ground up as an electric vehicle, begins deliveries in mid-2012. Add to Digg Bookmark with del.icio.us Add to Newsvine

......................... Enjoy and Stay Profitable, Mark Kabbash CEO Equitygroups.com Your Investor Social Network Follow Me http://twitter.com/#!/EquityGroups4U I am not an investment adviser.  Please check with your broker also please check the disclaimers within this site.  http://bit.ly/igC0Cs Any suggestions or comments?  Please send them to me.

Is Riverbed A Good Short?

Riverbed off 28% will RVBD go down more?

Supports CareCore Nationals Healthy Move to a Completely Virtualized IT:

Riverbed delivers performance for the globally connected enterprise.

With Riverbed, enterprises can successfully and intelligently implement strategic initiatives such as virtualization, consolidation, cloud computing, and disaster recovery without fear of compromising performance. By giving enterprises the platform they need to understand, optimize and consolidate their IT, Riverbed helps enterprises to build a fast, fluid and dynamic IT architecture that aligns with the business needs of the organization.

Riverbed's award-winning solutions are available from more than 1000 partners worldwide, including resellers, service providers, and systems integrators, or directly from Riverbed.

Riverbed was founded in 2002 and is based in San Francisco, California.

“In a seasonally difficult quarter, we completed a major product cycle and achieved results within our guidance range,” said Jerry M. Kennelly, Riverbed president and CEO. “Looking ahead, we expect our new Steelhead, Granite, and Cascade products, along with Stingray and Whitewater, to form the basis for Riverbed's next leg of growth as we continue to execute on our vision to deliver a complete performance platform. Our competitive position is strong, our addressable market is growing, and we are optimistic about the opportunity before us.” Riverbed Technology Reports First Quarter 2012 Results

Riverbed Technology, Inc. (RVBD)

 -NasdaqGS

19.85  8.01(28.75%) Apr 20, 4:00PM EDT|After Hours: 19.86  0.01 (0.05%) Apr 20, 7:59PM EDT

Is RVBD A Good Short? 

RVBD Off 26%: Seven Downgrades; Bulls Look to New Products ttp://on.barrons.com/I2GGqA

Does Riverbed Technology Deserve This Punishment? http://bit.ly/I2H7Bm

http://bit.ly/I2FJP5 #RVBD @riverbed #Agoodshort?

GGHO : Genesis Group Board of Directors Provides Outlook for 2012

Dear Genesis Group Holdings Shareholders: We would like to take a moment to review 2011; which was a transformative year for Genesis Group Holdings, Inc. (otcbb: ggho) and to look ahead to 2012 and beyond. We began 2011 with one operating entity, Digital Comm, Inc., that had produced approximately $950k in revenues in 2010. We finished 2011 with three operating subsidiaries producing approximately $6 million in revenue. We are expected to substantially exceed those numbers in 2012. New Financing In July, 2011 the Company entered into a definitive master funding agreement with Tekmark� Global Solutions, llc (Tekmark) and mmd Genesis llc. Pursuant to the parties' funding agreement, the Company received financing in the original principal amount of up to $2,000,000 from Tekmark and a line of credit in the original principal amount of up to $1,000,000 from mmd Genesis llc. The financing arrangement was geared towards the development and expansion of the Company's wireless....

http://www.equitygroups.com/GGHO-discussion/GGHO-Genesis-Group-Board-of-Directors-Provides-Outlook-for-2012

Hipcricket Named “Mobile Service Provider of the Year” by Mobile Marketer

Mobile Marketer also honored Macy’s, a Hipcricket client, as the 2011 “Mobile Marketer of the Year.” The publication lauded Hipcricket for its ability to deliver measurable value for its many clients—in particular its “notable efforts” with Macy’s Backstage Pass and Le Club Perrier—through cross-channel campaigns across all mobile media, stating, “Hipcricket’s continued push to integrate mobile in all channels for clients is worthy of emulation.” Hipcricket’s acquisition by Augme Technologies, as well as the company’s “effective branding, marketing and public relations,” were also recognized. “Being named the ‘Mobile Service Provider of the Year’ by Mobile Marketer is a tremendous honor for Hipcricket, one that recognizes our entire organization—including the technology, client engagement, creative and operations teams,” said Eric Harber, Chief Operating Officer of Hipcricket. “Our team continues to lead mobile marketing in new, scalable an

http://onlywire.com/r/62109418

Apple’s Mac App Store Downloads Top 100 Million

“In just three years the App Store changed how people get mobile apps, and now the Mac App Store is changing the traditional pc software industry,” said Philip Schiller, Apple’s senior vice president of Worldwide Marketing. “With more than 100 million downloads in less than a year, the Mac App Store is the largest and fastest growing pc software store in the world.”
http://www.equitygroups.com/AAPL-discussion/AAPL--Apples-Mac-App-Store-Downloads-Top-100-MillionApple MacBook Pro 2.4GHz Intel Core i7 Quad-Core Silver Notebook Computer - Z0NM0001K

Vicals VaxfectinR Demonstrates Potential as Universal Adjuvant, VICL DNA-BASED Vaccines

Vicals (VICL) researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor.  The company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models. Vaxfectin®-formulated H5N1 influenza DNA vaccines were well-tolerated and elicited durable immune responses within the predicted protective range in initial human studies.

"Vaxfectin® has many of the desired features of a successful adjuvant," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Executive Vice President of Product Development, "including the ability to significantly improve immune responses and favor specific types of immune responses. With a promising safety profile in preclinical and initial clinical studies, ease of formulation, stability and low manufacturing costs, Vaxfectin® is well-positioned as a potential 'universal' adjuvant for either immune enhancement or dose sparing applications in a broad range of infectious disease and cancer vaccines. A comprehensive new review of Vaxfectin® results published in the journal Expert Opinion on Drug Delivery[1] details Vaxfectin®'s development to date and should help us expand our outreach to potential licensees."

Vaxfectin® has been shown in multiple animal models to significantly increase the antibody and T-cell immune responses to antigens expressed from plasmid DNA vaccines. Results from two Phase 1 clinical trials of Vaxfectin®-formulated H5N1 influenza DNA vaccines demonstrated strong antibody responses and achieved T-cell responses in 75% to 100% of subjects in various dose cohorts. Vaxfectin® has demonstrated similar effect with protein-based vaccines, and the formulation can be adjusted to favor specific immune responses. The current publication reviews non-clinical immunological and efficacy studies of Vaxfectin® in several infectious disease and cancer models, preclinical safety and toxicology studies, clinical development of Vaxfectin®-formulated DNA vaccines, and studies of Vaxfectin®'s mechanism of action.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs.

Apple and the Christmas effect AAPL could rake it in this season

http://www.equitygroups.com/index.php?a=topic&t=168783

I would not be surprised to hear about "record" iTune sales this season. It wouldn't surprise me either if the entire product line of Apple does better than expected. Tizz the Season. Now what does that mean to the common share price? Time will tell. AAPL almost traded at $300 level twice. Is that a support level? Are we in a trading range? Is it better to stay in this range for a while than POW!



What are your thoughts?

See this Amp at http://bit.ly/dIJ8c5

VNLC Future Car Challenge Valence TechnologyPowered eVito Taxi Takes Home a Win

http://www.equitygroups.com/index.php?a=topic&t=168777#p0

Nov. 19, 2010 (Business Wire) -- Valence Technology, Inc. (NASDAQ: VLNC), a leading U.S.-based manufacturer of advanced energy storage solutions, announced today that the Mercedes Electric Vito (eVito) Taxi – a seven-seat electric vehicle powered by Valence batteries – was awarded Most Economic & Environment Friendly Multi-Purpose Electric Vehicle at the Royal Automobile Club’s (RAC) Future Car Challenge. Held in the United Kingdom earlier this month, the Future Car Challenge drew a crowd estimated at more than 250,000.

The class-winning Zytek Mercedes eVito taxi, powered by Valence batteries.

See this Amp at http://bit.ly/h8c3S6

About Valence Technology, Inc.:

Valence Technology is a global leader in the development and manufacture of safe, long-life lithium iron magnesium phosphate advanced energy storage solutions and integrated command and control logic. Headquartered in Austin, Texas, Valence enables and powers some of the world's most innovative and environmentally friendly applications, ranging from commercial electric vehicles to industrial and marine equipment. Valence Technology today offers a proven technology and manufacturing infrastructure that delivers ISO-certified products and processes that are protected by an extensive global patent portfolio. In addition to the corporate headquarters in Texas, Valence Technology has its Research & Development Center in Nevada, its Europe/Asia Pacific Sales office in Northern Ireland and global fulfillment centers in North America and Europe. Valence Technology is traded on the NASDAQ Capital Market under the ticker symbol "VLNC." For more information

EMKR Solar EMCORE Enters Agreement Establish Its Suncore Joint Venture in China

http://www.equitygroups.com/index.php?a=topic&t=168721#p0

..."China is viewed as one of the most promising markets for CPV solar power," said Dr. Hong Q. Hou, President and CEO of EMCORE. "This Agreement demonstrates Huainan's strategy and commitment to the growth of its renewable energy industry. These financial incentives will accelerate the commercialization of EMCORE's CPV technology and production ramp. We believe that this investment by Huainan and the establishment of Suncore's low cost manufacturing operation, will enable our CPV technology to become a cost effective solution for commercial and power utility applications," added Dr. Hou. ...

See this Amp at http://bit.ly/fX9iGo

Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma

Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma: "Stem Cell Transplantation in Treatment of NonHodgkins Lymphoma, SPPI Stem Cell Stock"

Prior to stem cell transplantation to a patient, the existing disease must be eradicated. Therefore, patients undergo conditioning regimens to eliminate, in the case of blood cancers, all or most of the tumor cells. This also destroys the patient’s blood generating (hematopoietic) system. Following conditioning, stem cells either derived from the patient’s own system (autologous) or from a matched donor (allogeneic) are introduced to the patient to renew the hematopoietic system. 

“These data solidify the role of ZEVALIN in treatment regimens for lymphoma patients,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals, Inc. “These presentations confirm our belief that ZEVALIN will continue to show strong data in a range of protocols to prepare lymphoma patients for these life-saving procedures.” 

Ajay K. Gopal, MD, Assistant Professor of Medical Oncology at the University of Washington School of Medicine and an Assistant Member of the Clinical Research Division of the Fred Hutchinson Cancer Research Center, presented data on the use of ZEVALIN, Fludarabine, and TBI based Non-Myeloablative Allogenic Transplant Conditioning for High-Risk B-Cell lymphomas (n=40). Non-myeloablative allogeneic transplantation (NMAT) can provide prolonged remissions in patients with advanced B-cell lymphoma via the graft versus lymphoma effect, though patients and donors need to be carefully selected. Dr. Gopal’s data indicated that use of ZEVALIN in NMAT is safe and feasible, and can lead to early objective responses and prolonged disease control in a subset of patients. 

Dr. Gopal’s ASH presentation is entitled Y-90 Ibritumomab Tiuxetan, Fludarabine, and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma. ASH Abstract #33.